Literature DB >> 18094739

A five year review of clinical profile in HSP.

N Grover1, N Sankhyan, J P Bisht.   

Abstract

To study the clinical profile of Henoch Schönlein Purpura [HSP] in children. A retrospective case series of 30 consecutive children with a diagnosis of HSP, with special focus on clinical manifestations. Two cases with unusual features are described in detail. Data of 19 boys and 11 girls with a mean age of 10.55 years was reviewed. Overall skin was involved in 100%, joints in 86.7%, GIT in 80% and renal system in 30% Two-thirds had palpable purpura at presentation. The mean duration of appearance of skin lesions after preceding joint and gastrointestinal symptoms was 8.6 days and 6.6 days respectively. Abdominal pain was the most common gastrointestinal symptom. Knee and ankle involvement occurred in more than 3/4th of the patients with arthritis. Vesciculobullous lesions were seen in two patients while one patient had rheumatic fever. Most children with HSP will have classical manifestation of the disease but diagnostic confusion can occur in those with atypical or absent cutaneous features at the onset.

Entities:  

Mesh:

Year:  2007        PMID: 18094739

Source DB:  PubMed          Journal:  JNMA J Nepal Med Assoc        ISSN: 0028-2715            Impact factor:   0.406


  3 in total

1.  Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children.

Authors:  Xu Teng; Cuiyun Gao; Mei Sun; Jie Wu
Journal:  Clin Rheumatol       Date:  2017-10-10       Impact factor: 2.980

2.  Late Relapse of Henoch-Schönlein Purpura in an Adolescent Presenting as Severe Gastroduodenitis.

Authors:  Chiara Rubino; Monica Paci; Massimo Resti; Paolo Lionetti; Sandra Trapani
Journal:  Front Pediatr       Date:  2018-11-20       Impact factor: 3.418

3.  Coupling Mechanism of Electromagnetic Field and Thermal Stress on Drosophila melanogaster.

Authors:  Zi-Yan Zhang; Jing Zhang; Chuan-Jun Yang; Hui-Yong Lian; Hui Yu; Xiao-Mei Huang; Peng Cai
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.